The conversation we aren't having enough: BODY RECOMPOSITION I see so much focus on one number: “How much weight did I lose?” But here's the question I want you to start asking instead: What is my body made of now? Because you can lose 20 pounds and still not have the body composition you were hoping for. A GLP-1 can help tremendously with appetite, calorie intake and weight loss. But your ultimate goal probably isn't simply to weigh less. It's to have: ↓ Body fat ↓ Visceral/abdominal fat ↑ Lean muscle ↑ Strength ↑ Metabolic health That's body recomposition — and it's why I've been talking so much about the difference between losing weight and actually changing your body. 🧠 ENTER THE GROWTH HORMONE AXIS Growth hormone isn't just something kids need to grow. In adults, the GH → IGF-1 axis plays an important role in body composition, fat metabolism and maintenance of lean tissue. We have particularly strong evidence for this in adults with true growth-hormone deficiency: randomized-trial data show GH replacement can increase lean body mass while decreasing fat mass. But your body doesn't normally release GH continuously. It pulses it. Think of the system as having a gas pedal and a brake: GHRH = GO → tells the pituitary to release GH. Somatostatin = STOP → suppresses GH release. Then GH stimulates production of IGF-1, which carries out many of GH's downstream effects and participates in the feedback loop. And this is where several peptides you've probably seen in The Blueprint Lab start making more sense. 🔬 IPAMORELIN Works through the ghrelin/GHS-R receptor pathway to trigger a pulse of GH release. Human research demonstrates a distinct episode of GH release after ipamorelin administration. 🔬 CJC-1295 A GHRH analog — essentially approaching GH release through the GHRH side of the pathway. CJC-1295 has been studied in healthy adults and produced substantial increases in both GH and IGF-1. 🔬 WHY CJC + IPAMORELIN GET PAIRED Now the stack makes more sense. You're approaching the GH axis through two different signaling pathways rather than simply thinking, “two peptides must be better than one.”